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The maturation of coronavirus SARS‑CoV‑2, which is the etiological agent at the origin of the COVID‑
19 pandemic, requires a main protease  Mpro to cleave the virus‑encoded polyproteins. Despite a 
wealth of experimental information already available, there is wide disagreement about the  Mpro 
monomer‑dimer equilibrium dissociation constant. Since the functional unit of  Mpro is a homodimer, 
the detailed knowledge of the thermodynamics of this equilibrium is a key piece of information for 
possible therapeutic intervention, with small molecules interfering with dimerization being potential 
broad‑spectrum antiviral drug leads. In the present study, we exploit Small Angle X‑ray Scattering 
(SAXS) to investigate the structural features of SARS‑CoV‑2  Mpro in solution as a function of protein 
concentration and temperature. A detailed thermodynamic picture of the monomer‑dimer equilibrium 
is derived, together with the temperature‑dependent value of the dissociation constant. SAXS is 
also used to study how the  Mpro dissociation process is affected by small inhibitors selected by virtual 
screening. We find that these inhibitors affect dimerization and enzymatic activity to a different extent 
and sometimes in an opposite way, likely due to the different molecular mechanisms underlying the 
two processes. The  Mpro residues that emerge as key to optimize both dissociation and enzymatic 
activity inhibition are discussed.
The COVID-19 pandemic is the ongoing worldwide health emergency caused by the coronavirus SARS-CoV-2 
(severe acute respiratory syndrome-cororavirus-2)1,2. Coronaviruses (CoVs) are enveloped positive-stranded 
RNA viruses; once the virion gets into the cell, the single-strand RNA translates into two overlapping polypro-
teins, termed pp1a and pp1ab, which mediate viral replication and proliferation. The virus maturation involves 
a highly complex cascade of proteolytic processing events on these polyproteins: most cleavage events are ruled 
by a nonstructural protein, the CoV main protease  (Mpro, also known as 3CLpro ), a three-domain (domains I 
to III)  protein3. The enzyme shows first autolytic cleavage from pp1a and pp1ab, then starts processing the two 
polyproteins at no less than 11 conserved  sites3.
Because of this mechanism of action, inhibiting  Mpro might lead to an attenuation of the viral infection. 
Indeed, this enzyme is a very attractive target for anti-CoV drug design: the  Mpro sequence is highly conserved 
among various  CoVs4, as mutations of  Mpro turn out to be often fatal for the  virus5. Thus, the risk of mutation-
mediated drug resistance is very low and inhibitors will display broad-spectrum antiviral activity. In addition, 
 Mpro inhibitors are unlikely to be toxic because human proteases have different cleavage specificity. A second 
point should be however considered: the published X-ray structures of SARS-CoV-2  Mpro, obtained both in the 
presence and in the absence of  inhibitors6,7, revealed that two  Mpro monomers form a functional active homodi-
mer, as already detected in different  coronaviruses3, which share with SARS-CoV  Mpro almost all the amino-
acids involved in the dimerization. In such homodimer, the two monomers are arranged almost perpendicular 
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to each  other7 and each monomer comprises the catalytic dyad His41-Cys145 and the substrate-binding site 
located in a cleft between domains I and II. Domain III, which contains five α-helices arranged into a globular 
cluster, is directly involved in controlling the dimerization of  Mpro mainly through a salt-bridge between Glu290 
of one monomer and Arg4 of the  other8. Quite remarkably, while individual monomers are enzymatically inac-
tive,  Mpro is active in the dimeric form. The structural reason behind the functionality of the dimer is probably 
due to the interaction of the N-finger of each of the two monomers with Glu166 of the other monomer, which 
establishes the shape of the so-called S1 pocket of the substrate-binding  site9. To approach this interaction site, 
the N-terminal amino acid residues are squeezed in between domains II and III of the parent monomer and 
domain II of the other  monomer7.
According to these considerations, two different strategies have been considered for the development of 
therapeutic agents: first, direct inhibition of the catalytic site by using molecules targeting the substrate binding 
pocket; second, attenuation of the catalytic activity by using inhibitors targeting the dimerization site. The second 
alternative is strictly related to the  Mpro equilibrium between dimers and monomers in solution. The thermo-
dynamic equilibrium of  Mpro dissociation process has been recently studied by analytical ultracentrifugation. 
Sedimentation velocity experiments provided a value of about 2.5 µ M for the apparent dimer dissociation con-
stant KD7. However, a more recent estimate by mass-spectrometry based assays established for KD a much lower 
value of 0.14± 0.03 µ M, indicating that  Mpro has a stronger preference to dimerize in solution than expected. 
In the case of SARS-CoV  Mpro, an even wider discrepancy among the different estimates of the dimer-monomer 
dissociation constants has been observed, with the values of KD provided by various experimental techniques 
falling in a range from 230± 30 µM10 down to 0.19± 0.03 µM11. In this framework, synchrotron Small Angle 
X-ray Scattering (SAXS) can be a very sharp method to determine  Mpro dimer-monomer equilibrium in solution. 
In fact, beyond pioneering SAXS studies performed also by some of us to investigate the thermodynamic features 
related to β-lactoglobulin  dimerization12–15, this approach has more recently provided noticeable information in 
many  issues16,17. Among them it is worth citing the case of A3G, a key enzyme for HIV-1  infection18, of LRRK2 
protein, linked to Parkinson’s  disease19. Hence, given the above mentioned uncertainty on the KD value that 
rules  Mpro dimerization, we decided to take advantage of SAXS to provide new insights on the SARS-CoV-2 
 Mpro dimer-monomer equilibrium. The study was performed both in the absence and in the presence of a set 
of in-silico selected small inhibitors, whose activity was spectroscopically assayed, in order to simultaneously 
test their therapeutic potential with respect to dimerization inhibition. By measuring the large-scale structural 
features of SARS-CoV-2  Mpro as a function of temperature, protein concentration and in the presence of differ-
ent amounts of inhibitors we provide an accurate thermodynamic picture of the SARS-CoV-2  Mpro inhibitor-
dependent dimerization process.
Results
Our biophysical multi-technique approach, mainly based on SAXS, by which we studied the effects of potential 
inhibitors of the SARS-CoV-2  Mpro on the dimerization process and the connection with the catalytic activity, 
is reported in the flowchart shown in Fig. 1. We have first derived the thermodynamic parameters controlling 
Figure 1.  Graphic display of the flowchart of the biophysical method described in the text.
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the  Mpro dimer-monomer equilibrium in solution by SAXS and CD spectroscopy techniques in the absence 
of inhibitors. Considering the results obtained by Graziano et al.20 for the SARS-CoV  Mpro, we have chosen to 
investigate a range of protein concentrations from 3 and 30 µ M, the molarity being expressed in terms of  Mpro 
monomers. It should be noted that, using these protein concentrations, one can discriminate between values of 
the dissociation constant that fall in the quite wide range of ≈ 0.2− 200 µ M (see Eq. 2).
Subsequently, we have studied by SAXS experiments the  Mpro dimer-monomer equilibrium in the presence 
of a series of potential inhibitors, selected from an in-house database containing commercial and synthetic 
compounds. Just one protein concentration, 30 µ M, and two concentrations of inhibitors, 30 and 60 µ M, cor-
responding to an inhibitors-to-monomer  Mpro molar ratio of 1 and 2, have been investigated. Activity assays 
were also performed and results are correlated with the  Mpro dimerization inhibition.
Mpro dimerization and thermal stability. The dimer-monomer equilibrium of SARS-CoV-2  Mpro has 
been investigated at different protein concentrations by performing in-solution SAXS experiments in the tem-
perature range between 15◦ and 45◦ C and far-UV CD measurements at room temperature. Far-UV CD spec-
troscopy was also used to study the  Mpro thermal stability, monitoring the unfolding transition between 10◦ and 
80◦ C.
SAXS. SAXS data of SARS-CoV-2  Mpro recorded at the B21 beam-line of the Diamond Synchrotron (Didctot, 
UK) at different protein concentrations and temperatures are shown as log-log plots in Fig. 2, top panels.
We have assumed that SAXS curves arise from both  Mpro monomer and dimer species, according to the 
thermodynamic equilibrium dissociation process given by the relationship:
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Figure 2.  SAXS data and fits. Top panels: SAXS experimental data of SARS-CoV-2  Mpro without inhibitors 
and best theoretical fits obtained by GENFIT  software21,22 (solid black and white lines). Each panel reports 
a dataset obtained at the same temperature, as shown in the top left corner, and at different nominal protein 
concentration C◦ . Bottom panels: SAXS data of  Mpro at fixed concentration C◦=30 µ M in the presence of 
inhibitors. Each panel reports the curves at the same temperature, shown in the bottom left corner. Red, green, 
blue, orange, dark-green, cyan and magenta refers to inhibitor 1, 2, 3, 4, 5, 6 and 7, respectively. Thin and thick 
lines refer to inhibitor concentrations CI of 30 and 60 µ M, respectively. Subsequent curves are multiplied by a 
factor 3.0 for clarity. Solid black and white lines are the best fits obtained by  GENFIT21.
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where C is the total molar concentration of monomers, x1 is the molar fraction of proteins that remain in the 
monomeric state, GD is the dissociation Gibbs free energy change, R is the universal gas constant and T the 
absolute temperature. To note, Eq. (2) can be solved in terms of x1,
According to classical thermodynamics, the temperature dependence of GD is
where G◦D = −RT◦ log K◦D is the dissociation Gibbs free energy at the reference temperature T◦ = 298.15 K 
( K◦D being the associated equilibrium constant), CpD is the change of the constant pressure heat capacity upon 
dissociation (here supposed independent on T) and S◦D is the dissociation entropy at T◦.
The macroscopic differential scattering cross section, which is the experimental information provided by a 
SAXS curve, for a system of interacting monomers and dimers can be written as
NA being Avogadro’s number, κ an unknown fraction of the nominal protein molar concentration CN ( C = κCN ), 
B an arbitrary flat background that takes into account possible uncertainties in the determination of transmis-
sions of proteins and buffers samples. P(q) represents the average form factor of the system
where Pj(q) stands for the form factor (which is the orientational average of the excess squared X-ray scattering 
amplitude) of the  Mpro monomer ( j = 1 ) or dimer ( j = 2 ). We have calculated Pj(q) from the the crystal structure 
of SARS-CoV-2  Mpro dimer recently  determined7 (PDB code 6y2e) considering one chain ( j = 1 ) or both chains 
( j = 2 ) by means of the SASMOL  method23. This method takes into account the contribution to the scattering 
due to the hydration water molecules around the protein, whose positions are found by embedding the atomic 
structure in a tetrahedral close packed lattice. For SARS-CoV-2  Mpro monomer and dimer, 726 and 1243 hydra-
tion water molecules have been respectively calculated, suggesting that for the dimer formation about 200 water 
molecules are removed from the hydration shell of both monomers. Hence, the water molecules attributed to 
each monomer decrease from 726 to 621 upon  Mpro dimerization. This indicates that the dimerization process 
is accompanied with slight structural changes reducing the average area accessible to solvent. The SM(q) term in 
Eq. (5) is the so-called “measured” structure factor, which describes the long range intermolecular interactions 
among all the particles in solution. For sake of simplicity, here we consider a common effective structure factor 
that takes into account monomer-monomer, monomer-dimer and dimer-dimer interactions. Considering that 
at low q all the experimental scattering curves (Fig. 2 top panels) show a positive deviation from a Guinier trend, 
indicative of the prevalence of protein-protein attraction with respect to repulsion, we have approximated the 
structure factor by the one of fractal distribution of inhomogeneities developed by  Teixeira24, whose main param-
eters are D, the fractal dimension of the aggregates, r0 , the effective radius of the aggregating protein molecule and 
ξ , the correlation length, which can be interpreted as the average size of the aggregates (see Eqs. 10, 11 and 12).
The above described model, which combines SARS-CoV-2  Mpro thermodynamic and structural features, has 
been adopted to simultaneously analyze the whole set of the SAXS curves, recorded at different temperatures and 
concentrations, shown in Fig. 2, top panels. Fitting parameters shared by all the curves are K◦D , the dissociation 
equilibrium constant at T◦ , CpD , the constant pressure heat capacity upon dissociation, S
◦
D and the dissociation 
entropy at T◦ . Another parameter common to all the curves is the relative mass density of the hydration water (in 
general higher than 1), dh , which is taken into account in the SASMOL  method23. The shared fitted parameters 
are shown in Table 1, while all the other are reported in Supplementary Table S1.
The most important parameter obtained by the simultaneous fit of SAXS data is the dissociation constant 
K◦D , which turns out to be 7± 1 µ M, in good agreement with the value obtained by Graziano et al.20 on the very 
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Table 1.  Thermodynamic parameters resulting from the global fit of SAXS data for SARS-CoV-2  Mpro without 
inhibitors at different temperatures and concentrations.
K◦D (µM) 7 ± 1
CpD (kJ mol
−1 K−1) 1.7 ± 0.7
S◦D (J mol−1 K−1) 50 ± 20
dh 1.100 ± 0.006
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Eq. 2) is G◦D ≃ 30 kJ mol
−1 , a value quite similar to the one observed for the β-lactoglobulin dimer dissocia-
tion at neutral  pH25. Regarding the dissociation entropy, we have obtained a positive value, 50± 20 J mol−1 K−1 , 
meaningfully smaller with respect to the one derived for the above mentioned β-lactoglobulin  case25. It should 
be noticed that in a dissociation process, many factors besides translational and rotational motions contribute 
to a positive dissociation entropy and it is difficult to separate them. One such factor is certainly the removal of 
about 200 hydration water molecules from the monomer-monomer interface when the dimer is formed. The 
change of the heat capacity at constant pressure upon dissociation resulted positive and large. This parameter 
indirectly describes the monomer-monomer interface, as it can be attributed to the hydration and correlates 
with the interface  size26. The set of parameters reported in Table 1 allows to calculate the  Mpro equilibrium dis-
sociation constant, together with its standard deviation, at any temperature. Results are shown in Supplementary 
Fig. S1, top left panel. We notice a slight increase of KD with T, an effect that is mainly due to the large increase 
of the constant pressure heat capacity upon dissociation. However, a further investigation on the monomer-
monomer interface area and its relationship with the dissociation heat  capacity27 requires further calorimetric 
experiments in order to obtain lower estimation errors. Finally, the relative density of the hydration shell is little 
more than one, in agreement with previous literature results on globular  proteins28–30. The determination of the 
thermodynamic features of the dimer-monomer equilibrium of  Mpro, in conditions quite similar to those found 
in vivo, is a fundamental step to investigate the effects of drugs aimed to inhibit dimerization and underlines the 
importance to further investigate  Mpro monomer-monomer interface by in-solution techniques.
Far-UV CD. To provide further insights on the dimer-monomer equilibrium, we have measured the far-UV 
CD spectra of  Mpro at three different concentrations, as shown in Fig. 3, left panel.
At the higher concentration of  16 µ M, the ellipticity shows a minimum wavelength min at about 221 nm and 
a shoulder centered at about 208 nm, which are typical of proteins with α-helical and β-sheet  content31,32, fully 
consistent with the structural features of the SARS-CoV-2  Mpro7, in agreement with CD measurements of the 
same  enzyme33 and of the very much similar SARS-CoV  Mpro34. As concentration decreases, min shifts towards 
lower values, thus reporting an increase of the β-sheet component at the expense of the α-helical  content31. 
Quite interestingly, if we take the dissociation constant of KD = 7± 1 µ M, in the concentration range from 2.5 
to 16 µ M a decrease of about a factor 2 in the fraction of monomers is expected (from around 0.67 to 0.36, see 
Eq. 3). This large shift in the dimer-monomer populations can reasonably yield the changes occurring to the  Mpro 
secondary structure and revealed by CD spectroscopy. Within this working hypothesis, we can describe the min 
trend in terms of the dimer-monomer equilibrium through the following expression:
where we take a fixed value of KD = 7 µ M as estimated by SAXS, while minmon and mindim are the minimum wave-
length parameters corresponding to the monomer and the dimer spectra, respectively. As shown in the inset of 
Fig. 3 (left panel), the trend of the min values is fitted in an excellent way with Eq. (7).
The thermal stability of the  Mpro has been characterized by monitoring the signal at 221 nm of the  Mpro sample 
at 16 µ M concentration, within the simplified hypothesis that the melting curve arises mainly from dimers. The 
rather sharp transition we have obtained is shown in Fig. 3 (right panel) and clearly suggests a two-state model, 
where the dimer unfolds and yields two random-coil monomeric chains:




































































Figure 3.  CD data and fits. Left: far-UV CD spectra of SARS-CoV-2  Mpro at three different concentrations. The 
CD data are represented in molar ellipticity units. Inset: position of the minimum of the spectra as a function of 
the concentration (red circles). The continuous line represents an estimate of the minimum position based on 
Eq. (7). Results from the fit are: minmon = 216.4± 0.1 nm and mindim = 222.9± 0.1 nm. Right: Thermal melting 
of the SARS-CoV-2  Mpro (16 µ M concentration) followed by monitoring the far-UV CD signal at 221 nm. The 
continuous line results from the theoretical fitting model arising from Eq. (8).
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Considering the scheme 8, if we hypothesize that the dimer can unfold to two random-coil monomeric chains, 
we obtain an apparent melting temperature Tm of 50◦ C, with a melting Van’t Hoff enthalpy of Hv = 810± 60  
kJ/mol. This value is in good agreement with the Van’t Hoff enthalpy Hv ∼ 880 kJ/mol estimated through 
the equation �Hv = 4RT2mCp,max/�Hcal from DSC  measurements33. It is also worth of note that, by taking 
Hcal = 443 kJ/mol33, it turns out a ratio �Hv/�Hcal ∼ 1.8 : such a value larger than 1 is fully consistent with the 
unfolding transition coupled to the dimer dissociation. Quite interestingly, the thermal stability as revealed by 
CD measurements supports a view where about 90 the folded state in the temperature range investigated by SAXS 
experiments, i.e. up to 45◦ C, thus validating the model we used to interpret the corresponding scattering curves.
Mpro dimer‑monomer equilibrium in presence of inhibitors. In-silico inhibitor selection. To identify 
new inhibitors of SARS-CoV-2 main protease from a large in-house database, we applied the in silico protocol, 
recently proposed by some of  us35. The flowchart of the adopted protocol is depicted in Supplementary Fig. S2. 
As a first step, we performed molecular docking studies on the compounds present in the database to analyze 
their binding capability in the catalytic active site of the SARS-CoV-2  Mpro (PDB code 6y2f)7, as detailed in the 
Materials and Methods section. Supplementary Fig. S3 shows the 3D binding active site of SARS-CoV-2  Mpro 
co-crystallized with the native inhibitor 13b7 covalently bonded to Cys145. The ligand binds to the enzymatic 
catalytic cleft of the protease located between domains I and II. The 3D binding site representation (Supplemen-
tary Fig. S3) highlights the interactions with the amino acid residues involved in the inhibition mechanism, 
such as Met49, Met165, Glu166, His164, Phe140, Gly143 and the catalytic Cys145. It is noteworthy the presence 
of hydrogen bonds between the pyridone moiety of ligand and Glu166, which rules the catalytic activity driv-
ing the SARS-CoV-2  Mpro to adopt an inactive conformation. The resulting best docked molecules have been 
selected based on a docking score cut-off of −6.5 kcal/mol and submitted to ligand based approaches, by taking 
advantage of the web-service DRUDIT (DRUgs Discovery Tools), an open access virtual screening platform 
recently  developed36, which represents the evolution of previous well-established protocols based on molecular 
 descriptors37,38.
DRUDIT implements the ligand based template of SARS-CoV-2  Mpro, available in the Biotarget Finder tool, 
which has been recently proposed as a useful mean in the identification of new SARS-CoV-2  Mpro modulators. 
Subsequently, the ligands selected by molecular docking were submitted to DRUDIT, as elsewhere  reported35, 
allowing the evaluation of their affinity to SARS-CoV-2  Mpro by the values of Drudit Affinity Score (DAS). The 
features of the ligand-based approaches based on molecular descriptors enabled us to assess topological, thermo-
dynamic and charge-related characteristics of the ligands. Thus, two complementary standpoints in the evaluation 
of the binding capability (ligand- and structure-based) covered all the interaction aspects in the ligand-target 
complex. The top scored molecules (selected based on a DAS cut-off of 0.65) were processed by Induced Fit 
Docking (IFD) calculations to further screen the hits to submit to in-wet test. In Supplementary Fig. S4 and in 
Table 2 the seven best scored structures are reported. The analysis of the results in Table 2 shows as the selected 
compounds present similar overall scores ( IFD_score ). This confirms the robustness of the ligand-based approach 
exploited by DRUDIT, which is able to give an account of the receptor-ligand binding although it is based on 
molecular descriptors that, as known, do not take into consideration the 3D shape of the binding site.
Figure 4 reports the first two best scored molecules 3 and 7 (according to the IFD_score parameter) in the 
binding site (left panel) and their related amino-acid maps (right panel). The two molecules are deeply buried in 
the cleft of the substrate-binding pocket, but unlike the co-crystallized ligand 13b, they interact with a somehow 
different pattern of amino-acids. This evidence suggests that these compounds are not covalently bound to the 
SARS-CoV-2  Mpro catalytic site.
Mpro activity assays. The selected inhibitors have been tested for their efficacy to reduce the  Mpro activity. As 
reported in Fig. 5, the time dependence of substrate fluorescence after hydrolysis indicates that the catalytic 
activity of  Mpro changes in the presence of the selected compounds. In particular, compounds 2, 4, 5 and 7 
induced an irreversible inactivation of the enzyme, while compounds 1 and 6 resulted rather inactive. For two of 
the most effective compounds (2 and 7) inhibition tests have been carried out as a function of the concentration. 
Unfortunately, we have not been able to perform this test for compound 4, which shows the best inhibition effi-
cacy, as it produces a fluorescence signal that partially obscures that of the substrate. Results are shown in Fig. 6 
(left panel). Percent inhibition data have been fitted with the Hill equation, p(CI) = 100/(1+ (IC50/CI)n) , to 
Table 2.  IFD results for the seven selected inhibitors compared with the 13b compound.
Inhibitor Prime_Energy XPG_score IFD_score
1 −11527.6 −8.580 −584.958
2 −11360.0 −10.772 −578.774
3 −11674.5 −7.895 −591.618
4 −11497.2 −5.969 −580.827
5 −11517.1 −8.918 −584.772
6 −11489.6 −9.176 −583.655
7 −11561.2 −10.409 −588.468
13b −11736.3 −7.944 −594.758
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get the half maximal effective concentration, IC50 , and the Hill slope n. We obtained IC50 = 10.3± 0.2 µ M for 
2 and 15± 2 µ M for 7, with n = 5± 1 and 3± 1 , respectively. These values of n larger than one indicate that the 
binding is positively cooperative, in agreement with other recent experimental  results40.
SAXS. SAXS curves of SARS-CoV-2  Mpro at nominal concentration C◦ = 30 µ M and in the presence of each 
of the seven selected potential inhibitors, at concentrations CI = 30 µ M (thin lines) or 60 µ M (thick lines), are 
reported in the bottom panels of Fig. 2 as log-log plots. Each panel refers to a different temperature, as indicated. 
Unfortunately, some of the foreseen conditions are missing (e.g. SAXS curves of inhibitor 5 at 60 µM), due to an 
experimental problem with the sample injection in the beam-line capillary. SAXS data have been analysed with 
the same approach adopted for data without inhibitors, with the further assumption that, for each compound, 
the thermodynamic parameters are linear functions of its concentration CI , namely �G◦D = �G◦D,0(1+ αGCI) , 
�CpD = �CpD,0(1+ αCpCI) , and �S
◦
D = �S◦D,0(1+ αSCI) . The three terms G◦D,0 = −RT◦ log K◦D,0 , CpD,0 
and S◦D,0 are exactly the values already obtained from the analysis of SAXS data without inhibitors (reported 
in Table 1), and the three corresponding constant rates αG , αCp and αS are fitting parameters common to all the 
SAXS curves corresponding to the same inhibitor. The high quality of the fitting procedure can be appreciated 
in Fig. 2 (bottom panels), where the calculated SAXS curves are superposed to the experimental ones and the 
resulting thermodynamic common fitting parameters are shown in Table 3, first panel.
The inhibitors with the lowest negative values of αG (Table 3, first panel) are those that mostly favour dimer 
dissociation. Results reported in Table 3 suggest that compounds 1, 6, and 7 are, within the experimental error, 
mostly able to increase the dissociation equilibrium constant, which at CI = 30 µ M becomes as large as ≈ 15 µ M 
and, at CI = 60 µ M almost doubles its value, reaching ≈ 30 µ M. We indeed recall that, in the absence of inhibi-
tors, the value of K◦D,0 is 7± 1 µ M (Table 1). Inhibitor 5 is slightly less active: at CI = 60 µ M we found a dissocia-
tion equilibrium constant of ≈ 20 µ M. The other three compounds, namely 2, 3 and 4, show a value of αG close 
to 0, indicating that they do not affect in a significant way the dimer-monomer equilibrium of  Mpro. Despite the 
high uncertainties on αCp and αS , their negative values suggest that upon dissociation there are changes of heat 
capacity and of entropy smaller than those observed without inhibitors, indicating that inhibitors increase the 
monomer order. The temperature dependence of the equilibrium dissociation constant KD is reported, for each 
inhibitor, in Supplementary Fig. S1. The large uncertainties on the fitting parameters determines the presence of 
wide bands of uncertainty on the KD trends. This is particularly evident for inhibitor 5, since SAXS data have been 
Figure 4.  3D binding modes of best scored compounds 3 and 7 into SARS-CoV-2  Mpro active site (left) and 
corresponding amino acid maps (right). The picture is elaborated by Maestro Schrödinger, version 10.2 (2017)39.
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recorded only for one inhibitor concentration. Hence, a word of caution is necessary regarding the temperature 
dependence of KD in the presence of the seven inhibitors obtained by the SAXS analysis.
From a close inspection of the single curve parameters, reported in Supplementary Tables S1 and S2, we 
observe that the value of the correlation length ξ is in the range 3000-4500 Åand rather independent of the tem-
perature and the presence of the inhibitors. The fractal dimension is ≈ 2 , suggesting a two-dimensional fractal 
growth of protein clusters in the presence of inhibitors.
Discussion
The active site of  Mpro monomer, which is highly conserved in different coronaviruses, is typically composed 
of four subsites, referred to as S1 ′  , S1, S2, and  S441–43. They accommodate the corresponding domains P1 ′  , P1, 
P2, and P4 of the substrate or the ones of the inhibitor compound mimicking the  substrate44. The S1 ′  subsite is 
constituted by the two residues Thr24 and Thr25. The S1 subsite (also referred to as the S1  pocket43) is formed 
by the side chains of residues Phe140, Asn142, Glu166, His163 and His172 and by the main chains of Phe140 
and  Leu14144. As discussed by Sacco et al.43, S1 is considered a promising target for an inhibiting compound, 
as it can interact with both hydrophobic and hydrophilic groups. On the other hand, S2 is a hydrophobic sub-
site formed of the side chains of His41, Met49, Tyr54, Met165 and Asp187, while S4 is a small hydrophobic 
pocked that involves the side chains of Met165, Leu167, Phe185, Gln192 and  Gln18944. An unusual catalytic 
dyad, His41-Cys145, acts in the active site, where His41 is a proton acceptor whereas Cys145 is attacked by the 
Figure 5.  Fluorescence inhibition curves of the selected compounds, as indicated in each frame. The straight 
lines are the best fitting lines obtained considering data points comprised between the time indicated by the 
arrow and 30 min. The slope of the straight line is reported in each frame.
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carbonyl carbon of the substrate. Hence, a signature of the inhibiting power of a compound is its capability to 
form a covalent bond with  Cys14541, as very recently confirmed by Dai et al.42, who have found two promising 
inhibitors 11a and 11b. The importance of the protonation state of Cys145 as well as the network of hydrogen 
bonds between the catalytic site of  Mpro and inhibiting compounds has also been recently discussed by Kneller 
et al.45 by combining X-ray and neutron scattering data. On these grounds, the experimental results obtained in 
the present study, together with the structure of the seven inhibitors within the  Mpro active site determined by 
the refined molecular docking, can be discussed.
The interaction map of inhibitor 1 is shown in Supplementary Fig. S5. There are a total of 11 contacts with 
amino acids of  Mpro monomer (Ser1, Thr25, Thr26, Ser46, Asn119, Leu141, Asn142, Cys145, Pro168, Arg188, 
Gln192), 2 of them (Ser46, Asn119) are hydrogen bonds. The residues of the catalytic dyad and the four subsites 
in contact with 1 are: Cys145 (dyad, 1 of 2 (50 of 2 (50 5 (20 To note, these contacts involve only one of the 
residues of the catalytic dyad, Cys145, without a hydrogen bond, whereas for inhibitor 13b there is a hydrogen 
bond with Cys145 (Supplementary Fig. S3). It is also worth to notice that Ser1 is among the residues in contact 
with inhibitor 1: since the mutual interaction of Glu166 of one monomer and the N-finger residues of the other 
monomer, like Ser1, has been proven to shape the catalytic  cleft7, we argue that this compound could destabilize 
the dimer, consistently with the high value of K◦D = 26± 4 µ M at CI = 60 µ M. However, its enzymatic inhibition 
is very poor, as shown by the high similarity of the RFU slope with the one in the absence of inhibitors (Fig. 5). A 
possible explanation of this result could be the absence of any hydrogen bond with Cys145 as well as the absence 
of any contact with the residues of subsite S2.
Regarding inhibitor 2, the map of contacts shown in Supplementary Fig. S6 reveals a total of 10 interactions 
with the monomer chain (Met49, Asn142, Gly143, Cys145, Asp187, His164, Met165, Glu166, Arg188, Gln189); 
4 of them are hydrogen bonds (Asn142, His164, Glu166, Gln189) that do not involve the catalytic site. More 
in detail, the residues of the catalytic dyad and the four subsites in contact with 2 are: Cys145 (dyad, 1 of 2 (50 
Asn142 and Glu166 (S1, 2 of 6 (33 of 5 (60 We also note that 2 residues of S1, Asn142 and Glu166, interact with 
this inhibitor via a hydrogen bond. This evidence, together with the high number of contacts with S2 and S4, 
could explain the experimentally observed inhibition effect ( m = 5± 2 RFU/min, Fig. 5). To note, this compound 
does not modify the dimer-monomer equilibrium, being the fitting parameter αG almost 0 (Table 3) within the 
experimental error.
Turning now to inhibitor 3, we have found that it does not alter the native dissociation equilibrium of  Mpro 
( αG ≈ 0 , see Table 3) and also its inhibition effect, observed by fluorescence analysis, is week ( m = 23± 3 RFU/
min, slightly lower that the value in absence of inhibitors). The contact map of compound 3 (Fig. 4) shows a total 
of 12 interactions with the monomer chain (Thr24, Thr25, Thr26, His41, Ser46, Met49, Phe140, Leu141, Gly143, 
Met165, Leu167, Gln192), 2 of them being hydrogen bonds (Thr24, Ser46) and one (His41) a π − π stacking. 
The residues of the catalytic dyad and the four subsites in contact with 3 are: His41 (dyad, 1 of 2 (50 (S1 ′  , 2 of 2 
(100 His41, Met49 and Met165 (S2, 3 of 5 (60 (S4, 3 of 5 (60 We notice that with respect to compound 2, there 
are no hydrogen bonds with the five residues that stabilize the S1 pocket. This difference might be the reason 
for the weak inhibition effect.
Compound 4 is the most effective among the seven inhibitors ( m ≈ 0 , Fig. 5) even if it shows at CI = 30 µ M 
a dissociation equilibrium constant K◦D = 6± 2 µ M slightly lower than the one without inhibitors (see Table 1). 
Indeed the parameter αG is positive but very close to 0 within the experimental error (Table 3), suggesting that 
compound 4 provokes a very weak stabilizing effect of the dimer. The contact map (Supplementary Fig. S7) 
shows 11 interactions with the monomer chain (Thr25, Thr26, Leu27, His41, Ser46, Met165, Glu166, Pro168, 
Gln189, Thr190, Gln192), including one hydrogen bond (Gln189). The residues of the catalytic dyad and the 
four subsites in contact with 4 are: His41 (dyad, 1 of 2 (50 of 2 (50 (40 Only one of the five residues that stabilize 
the S1 pocket is among the ones in contact with this inhibitor, Glu166, which does not form a hydrogen bond. 
Table 3.  Top panel: common thermodynamic fitting parameters of the analysis of SAXS data for SARS-CoV-2 
 Mpro samples with inhibitors. Middle and bottom panels: dissociation constants derived by the analysis of 




1 −0.18± 0.02 −6± 3 −4± 1
2 −0.0± 0.1 −1± 3 −4± 1
3 0.00± 0.08 0± 4 −8± 4
4 0.0± 0.1 −2± 2 −1± 5
5 −0.14± 0.05 −1± 4 −4± 4
6 −0.20± 0.05 −6± 3 −1.7± 0.8
7 −0.19± 0.07 −3± 3 −5± 2
30 µ M Inhibitor 1 2 3 4 6 7
K◦D (µM) 14± 1 8± 3 7± 2 6± 2 15± 3 14± 3
60 µ M Inhibitor 1 2 3 4 5 6 7
K◦D (µM) 26± 4 8± 6 7± 4 5± 4 19± 7 30± 10 30± 10
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On this ground, the high inhibition effect of compound 4 could be only justified by the contact with His41, one 
of the two residues of the catalytic dyad.
Results are different for compound 5: at CI = 60 µ M (unfortunately no data are available at 30 µ M) it provokes 
a rather important increase of K◦D (Table 3) and shows a moderate inhibition effect ( m = 8± 3 RFU/min, see 
Fig. 5). Looking at the interaction map (Supplementary Fig. S8), we notice 11 interactions with monomer  Mpro 
(Thr25, Thr26, Leu27, His41, Asn142, Gly143, Met165, Glu166, Pro168, Arg188, Gln192), one of them regards 
Glu166, involved in two hydrogen bonds, and the other one His41, involved in two a π − π stacking interac-
tions. The residues of the catalytic dyad and the four subsites in contact with 5 are: His41 (dyad, 1 of 2 (50 of 
2 (50 Met165 (S2, 2 of 5 (40 There are not hydrogen bonds involving the five residues that stabilize the S1 site. 
One could speculate that this inhibitor, probably due to its steric hindrance, provokes a modification of S1 that 
could interfere with the enzymatic activity of  Mpro.
Compound 6 determines 11 contacts with the amino acid of the monomer (His41, Leu141, Ser144, Cys145, 
Met165, Glu166, Leu167, Arg188, Gln189, Ala191, Gln192, Supplementary Fig. S9), including two hydrogen 
bond (His41, Gln192). In particular, the residues of the catalytic dyad and the four subsites in contact with 6 are: 
His41 and Cys145 (dyad, 2 of 2 (100 2 of 5 (40 An almost absent inhibition effect is seen by fluorescence, being 
the slope of RFU (Fig. 5) very similar to the one determined in the absence of inhibitors. On the other side, com-
pound 6 is able to modify the dimer-monomer dissociation, with one of the highest values of K◦D = 30± 10 µ M 
at CI = 60 µ M (Table 3). To note, only one of the 6 amino acids that stabilize the S1 site are included in the list 
of residues interacting with compound 6. Hence, the absence of its inhibition activity could be explained by 
the small size of its molecular structure, which might not be able to provoke important modifications of the S1 
pocket and hence to modify the catalytic features of  Mpro.
We finally turn to compound 7. It shows an opposite behaviour with respect to compound 6: it is capable to 
change the dimer-monomer equilibrium at the same extent ( K◦D = 30± 10 µ M at CI = 60 µ M, Table 3) and 
displays a promising inhibition effect, with m ≈ 1 . For this compound, the map of contacts shows 12 interactions 
(Thr24, Thr25, Thr26, His41, Thr45, Met49, Leu141, His164, Met165, Glu166, Asp187, Arg188, Fig. 4) with a 
large number of hydrogen bonds (Thr24, Thr26, His41, His164, Glu166, Arg188). The residues of the catalytic 
dyad and the four subsites in contact with 7 are: His41 (dyad, 1 of 2 (50 (S1 ′  , 2 of 2 (100 His41, Met49, Met165 
and Asp187 (S2, 4 of 5 (80 5 (20 Only one of the interacting residues (Glu166) is involved in the stabilization 
of the S1 pocket. We can infer the high inhibition effect could be due to the high number of contact with S2 
and to the presence of 6 hydrogen bonds. Another hypothesis, which needs further insights to be confirmed, is 
that the fluorinated groups, which are present in a high number in compound 7, may originate a new reactive 
warhead able to form a covalent bond with Cys145. We may also consider that one of them involves a residue of 
the catalytic dyad, His41, suggesting a possible important modification of the enzymatic activity.
Conclusions
Considering the results that we have discussed above, a picture emerges where the selected compounds designed 
to bind the catalytic site of SARS-CoV-2  Mpro may affect dimerization and enzymatic activity processes to a 
different extent. Since the functional form of  Mpro is a dimer, compounds that disrupt dimerization should 
be in principle also effective at diminishing its catalytic activity. However, the compound-induced shift in the 
dimer and monomer thermal equilibrium populations may not directly translate into a loss of enzymatic activ-
ity. Indeed, the latter strongly depends also on the local interactions occurring at the catalytic site, that in turn 
governs the competition between inhibitor and substrate. To better visualize the scenario presented by our 
findings, we report in Fig. 6 (right panel) the slope m of the fluorescence inhibition curve as a function of the 
dimer-monomer equilibrium constant KD calculated from the set of fitting parameters, derived by the global fit 
of SAXS data of the seven compounds, by fixing the inhibitor concentration CI at 60 µ M and the temperature 
at 30◦ C, the same value employed in the enzymatic activity assays. The points in this map could be organized 
in two groups, as represented in blue and in red. The latter group refers to compounds 3, 5 and 7, which show 
the expected behaviour: the stronger is their capability to induce the dissociation of the  Mpro dimer, the more 
important is their inhibiting effect. For these compounds the molecular mechanisms underlying inhibition at the 
active site are likely linked with their ability to provoke dimer dissociation. On the other hand, for compounds 1, 
2, 4, and 6, displayed in blue, we find the opposite behavior: the increase of dimer dissociation does not determine 
an increase of inhibition, thus suggesting that the molecular mechanisms of inhibition at the active site play 
a major role with a marginal involvement of the monomer-monomer interface. This apparently contradictory 
result can be in part explained by considering that, in all cases, the dissociation equilibrium is weak so that, in 
the presence of a compound that alters the dimer-monomer equilibrium but that does not hamper the interac-
tion with the substrate, there are always dimeric  Mpro molecules that can exert their enzymatic activity when a 
substrate is available.
A further complementary explanation could be the existence of ligand binding sites alternative to the orthos-
teric active site located at the interface of dimeric  Mpro. Indeed, the presence of two of such binding sites, not 
directly involved in enzymatic inhibition but probably interfering with dimerization, has been very recently 
revealed by a molecular dynamics simulation study in the SARS-CoV-2  Mpro46.
We can provide a qualitative interpretation of the behavior exhibited by the two groups of compounds by 
looking at the contact maps of the residues grouped in the different sub-sites of the active site. We note that 
both compound 6 and 7, which show the higher values of KD , are in contact with two residues of the S1, Leu141 
and Glu166. Besides, compound 1, which has a slightly lower KD , interacts with S1 through the contacts with 
Leu141 and Asn142. This suggests that binding with at least two of the residues Glu166, Leu141 and Asn142 is 
crucial to modify the dimer-monomer equilibrium. On the other hand, the interaction of compounds 7, 2 and 
5 with Glu166 via an hydrogen bond is likely linked to their high inhibiting action. On the contrary, there is 
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no hydrogen bond between compound 6 and Glu166. Hence, on the basis of the results obtained for the seven 
selected compounds, the interplay between SAXS results, enzymatic activity assays and contact map analysis 
suggests a relevant clue: in order to promote both  Mpro dimer dissociation and the inhibition of its catalytic 
activity, a small molecule should interact with at least two residues of the S1 sub-site and most likely form an 
hydrogen bond with Glu166. The key role of Glu166 residue, which is conserved among all human coronaviruses, 
for inhibition has been pointed out also very  recently47.
To note, according to Goyal and  Goyal6, Glu166 is among the residues that should be targeted to inhibit the 
dimerization of SARS-CoV  Mpro. However, for a more detailed investigation of the dimerization process in sta-
bilizing the catalytic activity of  Mpro, it is also important to take into account the overall contribution of protein 
flexibility, as recently evidenced by Suárez et al.48, through a 2 µ s Molecular Dynamics simulation of  Mpro with 
and without a model peptide mimicking the enzyme substrate.
In summary, the experimental work presented here brings basic information to decipher the complex inter-
play between enzymatic activity inhibition and dimer dissociation. To the best of our knowledge, we have shown 
for the first time how structural information about the SARS-CoV-2  Mpro in solution in the absence and in the 
presence of potential inhibitors and as a function of temperature can be obtained from an advanced analysis of 
SAXS data within an overall thermodynamic picture, complemented by more conventional approaches. Our 
results suggest that more experimental evidences about the impairment of monomer and dimer  Mpro in the 
presence of inhibitors corroborated by computational information will be necessary for a deeper understanding 
of the  Mpro allosteric mechanism.
Materials and methods
Mpro expression and western blot analysis. pGEX-6P-1 vector harboring the full length cDNA 
sequence encoding for SARS-CoV-2 Main Protease  (Mpro NC_045512) was purchased from GenScript (clone 
ID_M16788F). The expressing vector was transformed into BL21DE3pLys Escherichia coli cells and the obtained 
clones were assayed both in small scale (5  mL) and medium scale (500  mL and 1  L) for the production of 
SARS-CoV-2  Mpro. Transformants were grown onto LB medium containing 100 µg/mL Ampicillin and 34 µg/
mL Chloramphenicol as selective antibiotics. Cultures were grown up to OD600 of 0.6-0.8 at 37◦ C, 200 rpm 
and then  Mpro expression was induced by addition of 0.5 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG). 
Growth under induction was achieved both for 3 h at 37◦ C and 10 h at 16◦ C in order to test the best expressing 
condition. Cells were harvested by centrifugation at 6000 g. Cell pellets were resuspended in lysis buffer (20 mM 
Tris-HCl pH 8.0, 300 mM NaCl, 2 mM β-mercaptoethanol), and cell rupture was achieved by sonication (Son-
ics Vibra Cell sonicator) at 4 ◦ C. Cell debris was separated from the total protein extract by centrifugation at 
6500 g for 1 h. Supernatant aliquotes were resuspended in Laemmli sample buffer, run onto 12 polyvinylidene 
difluoride membrane for Western blot analysis.  Mpro was decorated by 6 ×-His tag monoclonal primary antibody 
(Invitrogen) and anti-mouse secondary antibody and detected by chemiluminescence (Clarity Western ICL Sub-
strate, Biorad, Supplementary Fig. S11, panels A and B).
Mpro purification and His‑tag cleavage. The total cell extract was loaded onto Ni-NTA affinity column 
(G-Biosciences) and washed by washing buffer (Tris-HCl 20 mM pH 7.6, NaCl 100 mM).  Mpro was eluted by elu-
tion buffer (Tris-HCl 20 mM pH 7.6, NaCl 100 mM, 300 mM imidazole) in 5 fractions of 1 mL each. Aliquotes 
of elution fractions were loaded onto 12 acrylamide gel and imidazole was removed by dialysis against Prescis-
sion cleavage buffer (Tris-HCl 50 mM pH 8.0, NaCl 150 mM, dithiothreitol 1 mM, ethylenediaminetetraacetic 
Figure 6.  Left: percent inhibition data of SARS-CoV-2  Mpro as a function of the concentration of inhibitor 
2 (green points) and 7 (magenta points). Best fits with the Hill equation are shown as solid lines. Right: 
correlation map between the catalytic activity, represented by the RFU slope m, and dimer dissociation 
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acid 1 mM) through Amicon Ultra-4 centrifugal filters 30K (Merck Millipore). For  Mpro C-terminal His-tag 
removal, the Prescission (1 U for 100 µ g of protein) cleavage reaction was performed at 4 ◦ C for 4 h and Prescis-
sion protease was then removed by GSTrap FF column (GE-Healthcare). The  Mpro solution was further purified 
by FPLC size-exclusion chromatography on Superdex 75 10/300 GL column (Supplementary Fig. S10, panels A 
and B)33,44.
Mpro activity assay and inhibition. The fluorescently labelled auto-cleavage sequence of SARS-CoV-2 
 Mpro, ((7-Methoxycoumarin-4-yl)acetyl)-AVLQ↓SGFRK(2,4-dinitrophenyl)K (purchased from GenScript), was 
utilized to monitor the recombinant  Mpro kinetics (excitation 320 nm, emission 405 nm). The assay was started 
by mixing ≈ 0.2 µ M SARS-CoV-2  Mpro to different amounts of substrate (10, 20, 40 µ M) in order to set the 
best protein-substrate concentration to detect  Mpro  activity41. Fluorescence intensity was measured by DeNovix 
DS-11 FX+ fluorometer. The  Mpro activity reported as reference for inhibition tests was obtained by linear fitting 
of the fluorescence curve in the presence of 40 µ M of substrate  concentration33,41. Seven inhibitors dissolved 
in dimethyl sulfoxide (DMSO) were tested at a final concentration of 30 µM42 (Fig. 5). Each reaction in a final 
volume of 200 µ L was firstly incubated for 20 min at 30◦ C without substrate. After substrate addition, fluores-
cence intensities were reported as relative fluorescence units (RFU) and monitored every minute for a duration 
of 30 min at 30◦ C.
Circular dichroism. In-house circular dichroism experiments were performed at room temperature using 
a JASCO J-810 spectropolarimeter (Physics and Geology Department, University of Perugia). Quartz cuvettes 
with path-length of 1 mm was used, in order to obtain the optimum signal-to-noise ratio for the  Mpro sam-
ples with concentrations of 16, 6 and 2.5 µ M respectively. Protein concentration was measured by performing 
absorption measurements on the same samples, with an extinction coefficient of 33640 M−1 cm−1 estimated 
from amino acid sequence Expasy online ProtParam  tool49. Each spectrum was collected in the range from 200 
to 260 nm with a scan speed of 50 nm/min, and repeated three times. The CD data are represented in molar 
extinction units, by using the formula [�] = m◦/(10C L) , where m◦ is the ellipticity (in millidegree unit), C is 
the protein molar concentration and L is the path length of cell (in cm). The thermal stability has been studied at 
16 µ M  Mpro concentration, by varying the temperature through a thermal bath from 27◦ to 77◦ C.
Small angle X‑ray scattering. SAXS experiments were carried out at the B21 beam-line of the Diamond 
Synchrotron (Didctot, UK), operating with a fixed camera length (4.014 m) at 12.4 keV (  = 1.000 Å) and with 
a flux of ∼ 1012 photons per second. Samples were injected in the capillary (thickness 1.7 mm) by means of a 
robotic apparatus and measured 21 times with an exposure time of 1 min. The  Mpro samples without inhibitors 
were measured at the nominal monomer molar concentration of 3, 10, 20 and 30 µ M and at temperature of 15◦ , 
25◦ , 30◦ , 37◦ and 45◦ C. In the presence of inhibitors, SAXS curves were recorded at two  Mpro monomer molar 
concentrations, 30 and 60 µ M, and at three temperatures, 30◦ , 37◦ and 45◦ C.
SAXS data analysis approach has been described in the main text, with the exception of some minor points. 
Since in all conditions the nominal molar protein concentration is lower than 1 mM, its temperature variations 
can be considered to be only determined by the dependency with T of the relative mass density of water, which, 
according to literature  results50 is written as
where, in our investigated range 15− 45◦  C, the optimum value of the thermal expansivity at T◦ is 
αw = 2.5 · 10−4 K−1 and the one of its first derivative is βw = 9.8 · 10−6 K−2 . Accordingly, CN = C◦dw , C◦ being 
the nominal protein concentration at T◦.
The measured structure factor SM(q) has been obtained in relation to the protein-protein structure factor 
S(q) by:
where β(q) is the coupling function
and P(1)(q) is the average of the protein excess scattering amplitude, a function provided, together with P(q) by 
the SASMOL method. According to Ref.24, S(q) has been written as
where Ŵ(x) is the gamma function, D is the fractal dimension (comprised between 1 and 3) of the aggregates, r0 
is the effective radius of the aggregating protein and ξ is the correlation length.
In‑silico design. Ligand preparation. The default setting of the LigPrep tool implemented in Schrödinger’s 
software (version 2017-1) was used to prepare the ligands for  docking51. All possible tautomers and combination 
of stereoisomers were generated for pH 7.0± 0.4 , using the Epik ionization  method52. Energy minimization was 
subsequently performed using the integrated OPLS 2005 force  field53.
(9)dw =e−αw(T−T◦)−βw(T−T◦)
2/2,
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Protein preparation. The crystal structure of SARS-CoV-2  Mpro in complex with ligand 13b (PDB code 6y2f)7 
was downloaded from the Protein Data  Bank54. The cocrystal ligand, covalently bonded to Cys145, was treated 
by breaking the covalent bond and filling in open valence. Protein Preparation Wizard of Schrödinger software 
was subsequently employed for further preparations of the protein structure using the default  settings55. Bond 
orders were assigned, and hydrogen atoms as well as protonation of the heteroatom states were added using the 
Epik-tool (with the pH set at biologically relevant values, i.e. at 7.0± 0.4 ). The H-bond network was then opti-
mized. The structure was subjected to a restrained energy minimization step (RMSD of the atom displacement 
for terminating the minimization was 0.3 Å), using the Optimized Potentials for Liquid Simulations (OPLS) 
2005 force  field53.
Docking validation. Molecular Docking was performed by the Glide  program37,56,57. The receptor grid prepara-
tion was performed by assigning the original ligand (13b) as the centroid of the grid box. The generated 3D con-
formers were docked into the receptor model using the Standard Precision (XP) mode as the scoring function. 
A total of 5 poses per ligand conformer were included in the post-docking minimization step, and a maximum 
of 2 docking poses were generated for each ligand conformer. The proposed docking procedure was validated by 
the re-dock of the crystallized 13b within the receptor-binding pockets of 6y2f by Glide covalent docking. The 
results obtained were in good agreement of the experimental poses, showing a RMSD of 0.75 Å.
Biotarget finder module (DRUDIT). The refined selection of suitable SARS-CoV-2  Mpro inhibitors was per-
formed through the module Biotarget Finder as available in the www.drudit.com  webserver36. The tool allows 
to predict the binding affinity of candidate molecules versus the selected biological target. The template of the 
biological target was built as previously reported. Thus, the in-house database was submitted to the Biological 
Predictor module by setting the DRUDIT parameters, N, Z, and G, using the crystallized structure of 13b, as 
previously  reported35.
Induced fit docking. Induced fit docking simulation was performed using the IFD application as  available38,58 
in the Schrödinger software  suite39, which has been demonstrated to be an accurate and robust method to 
account for both ligand and receptor  flexibility59. The IFD protocol was performed as  follows60,61: the ligands 
were docked into the rigid receptor models with scaled down van der Waals (vdW) radii. The Glide Stand-
ard Precision (XP) mode was used for the docking and 20 ligand poses were retained for protein structural 
refinements. The docking boxes were defined to include all amino acid residues within the dimensions of 25 Å×
25 Å×25 Å from the centre of the original ligands. The induced-fit protein-ligand complexes were generated 
using Prime  software39,62,63. The 20 structures from the previous step were submitted to side chain and backbone 
refinements. All residues with at least one atom located within 5.0 Å of each corresponding ligand pose were 
included in the refinement by Prime. All the poses generated were then hierarchically classified, refined and 
further minimized into the active site grid before being finally scored using the proprietary GlideScore function 
defined as follows: XPG_score = 0.065 vdW + 0.130Coul + Lipo+Hbond +Metal + BuryP+ RotB+ Site , 
where vdW is the van der Waals energy term, Coul is the Coulomb energy, Lipo is a lipophilic contact term 
that rewards favourable hydrophobic interactions, Hbond is an H-bonding term, Metal is a metal-binding term 
(where applicable), BuryP is a penalty term applied to buried polar groups, RotB is a penalty for freezing rotat-
able bonds and Site is a term used to describe favourable polar interactions in the active site. Finally, IFD_score 
( IFD_score = XPG_score+ 0.05 Prime_Energy ), which accounts for both protein-ligand interaction energy 
and total energy of the system, was calculated and used to rank the IFD poses. More negative IFD_score values 
indicated more favourable binding. Results are shown in Table 2.
Chemical synthesis of inhibitors. Inhibitors 164, 364, 564 and 665 have been prepared as previously 
reported. Inhibitor 2 is commercial. Inhibitors 464 and 764 have been synthesized as described in detail in the next 
paragraphs. All solvent and reagents were used as received, unless otherwise stated. Melting points were deter-
mined on a hot-stage apparatus. 1H-NMR and 13C-NMR spectra were recorded at indicated frequencies, residual 
solvent peak was used as reference. Chromatography was performed by using silica gel (0.040-0.063 mm) and 
mixtures of ethyl acetate and petroleum ether (fraction boiling in the range of 40-60◦ C) in various ratios (v/v). 
Compounds 864 and 966, used in the synthesis of inhibitors 4 and 7, have been prepared as previously reported.
Synthesis of inhibitor 4. Inhibitor 4 was synthesized through a nucleophilic aromatic substitution  (SNAr) of 
5-pentafluorophenyl-1,2,4-oxadiazole 8 with 1-Aza-18-crown-6 in para position (Supplementary Fig.  S12). 
Oxadiazole 8 (312 mg, 1 mmol) was dissolved in acetonitrile (5 mL). 1-Aza-18-crown-6 (289 mg, 1.1 mmol) 
and potassium carbonate (152 mg, 1.1 mmol) were added and the suspension was stirred at room temperature 
for 24 h. The reaction was monitored by TLC. The reaction mixture was dried under vacuum and treated with 
H2 O (50 mL) before extraction three times with EtOAc (50 mL each). The combined organic layers were dried 
with Na2SO4 and then concentrated in vacuo to give the crude product, which was recrystallized from EtOH. 
16-(2,3,5,6-tetrafluoro-4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl)-1,4,7,10,13-pentaoxa-16-azacyclooctade-
cane: yield: 73 δ : 3.68-3.80 (m, 24H, overlapped −CH2− signals), 7.51-7.54 (m, 3H, Ar), 8.16-8.20 (m, 3H, Ar). 
FTIR (Nujol) 1647, 1529, 1518 cm−1 ; HRMS-ESI [(M+H)+ ]: m/z calculated for ( C26H30F4N2O6)+ : 556.2060; 
found, 556.2046.
Synthesis of inhibitor 7. Tripodal oxadiazolylamide (inhibitor 7) was easily obtained by means of nucleophilic 
displacement with ethylamine from tripodal ester 9, which was previously reported as heavy metal fluores-
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cent sensor (Supplementary Fig. S13)66. Tripodal 9 (101 mg, 0.1 mmol) was dissolved in acetonitrile (3 mL). 
Ethylamine (2 M in MeOH, 150 µ L, 0.3 mmol) was added and the solution was stirred at room temperature 
for 24 h. The reaction was monitored by TLC. The reaction mixture was dried under vacuum and treated with 
H2 O (50 mL) before extraction three times with EtOAc (50 mL each). The combined organic layers were dried 
with Na2SO4 and then concentrated in vacuo to give the crude product, which was purified by chromatogra-
phy. 5,5’,5”-(((nitrilotris(ethane-2,1-diyl))tris(azanediyl))tris(2,3,5,6-tetrafluorobenzene-4,1-diyl))tris(N-
ethyl-1,2,4-oxadiazole-3-carboxamide): yield: 66 d 6 ) δ: 1.18 (t, 9H, J = 6.9 Hz, CH3 ), 2.85 (bs, 6H, NCH2CH2
NH-), 3.34-3.48 (m, 6H, CH3CH2NH-), 3.56 (bs, 6H, NCH2CH2NH-), 6.91 (bs, 3H, NCH2CH2NH-), 9.02 (t, 
3H, J = 5.7 Hz, NHCH2CH3 ). FTIR (Nujol) 3325, 1701, 1680, 1647 cm−1 ; HRMS-ESI [(M+H)+ ]: m/z calcu-
lated for ( C39H34F12N13O6)+ : 1007.2485; found, 1007.2518.
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